{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:48:48Z","timestamp":1788922128505,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100007261","name":"New York Academy of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007261","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"DOI":"10.1186\/s12954-025-01300-1","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T05:06:35Z","timestamp":1756443995000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Gender differences regarding interest in opioid agonist treatment with hydromorphone: a cross-sectional study of syringe service program participants"],"prefix":"10.1186","volume":"22","author":[{"given":"Vitaliy","family":"Lasiychuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Ghiroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"L\u00f3pez-Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron D.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"1300_CR1","unstructured":"Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results from the 2023 National Survey on Drug Use and Health. 2024. Available from: https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/reports\/rpt47095\/National%20Report\/National%20Report\/2023-nsduh-annual-national.pdf. Accessed 30 July 2025."},{"key":"1300_CR2","doi-asserted-by":"publisher","first-page":"e244617","DOI":"10.1001\/jamanetworkopen.2024.4617","volume":"7","author":"N Nataraj","year":"2024","unstructured":"Nataraj N, Rikard SM, Zhang K, et al. Public health interventions and overdose-related outcomes among persons with opioid use disorder. JAMA Netw Open. 2024;7:e244617.","journal-title":"JAMA Netw Open"},{"key":"1300_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103786","volume":"110","author":"N Krawczyk","year":"2022","unstructured":"Krawczyk N, Rivera BD, Jent V, Keyes KM, Jones CM, Cerd\u00e1 M. Has the treatment gap for opioid use disorder narrowed in the U.S.? A yearly assessment from 2010 to 2019. Int J Drug Policy. 2022;110: 103786.","journal-title":"Int J Drug Policy"},{"issue":"14","key":"1300_CR4","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1001\/jama.2015.10345","volume":"314","author":"B Saloner","year":"2015","unstructured":"Saloner B, Karthikeyan S. Changes in substance abuse treatment use among individuals with opioid use disorders in the United States, 2004\u20132013. JAMA. 2015;314(14):1515.","journal-title":"JAMA"},{"issue":"4","key":"1300_CR5","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1056\/NEJMra1604339","volume":"375","author":"MA Schuckit","year":"2016","unstructured":"Schuckit MA. Treatment of opioid-use disorders. N Engl J Med. 2016;375(4):357\u201368.","journal-title":"N Engl J Med"},{"issue":"6","key":"1300_CR6","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/S2215-0366(23)00095-0","volume":"10","author":"L Degenhardt","year":"2023","unstructured":"Degenhardt L, Clark B, Macpherson G, Leppan O, Nielsen S, Zahra E, et al. Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies. Lancet Psychiatry. 2023;10(6):386\u2013402.","journal-title":"Lancet Psychiatry"},{"issue":"5","key":"1300_CR7","doi-asserted-by":"publisher","first-page":"e0232086","DOI":"10.1371\/journal.pone.0232086","volume":"15","author":"AM O\u2019Connor","year":"2020","unstructured":"O\u2019Connor AM, Cousins G, Durand L, Barry J, Boland F. Retention of patients in opioid substitution treatment: a systematic review. PLoS One. 2020;15(5):e0232086.","journal-title":"PLoS One"},{"key":"1300_CR8","doi-asserted-by":"publisher","first-page":"j1550","DOI":"10.1136\/bmj.j1550","volume":"357","author":"L Sordo","year":"2017","unstructured":"Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.","journal-title":"BMJ"},{"key":"1300_CR9","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jsat.2017.07.001","volume":"85","author":"JR Morgan","year":"2018","unstructured":"Morgan JR, Schackman BR, Leff JA, Linas BP, Walley AY. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a united States commercially insured population. J Subst Abuse Treat. 2018;85:90\u20136.","journal-title":"J Subst Abuse Treat"},{"key":"1300_CR10","unstructured":"National Center for Health Statistics. Centers for Disease Control and Prevention. US Overdose Deaths Decrease Almost 27% in 2024 [Press Release]; 2025 May 14. Available from: https:\/\/www.cdc.gov\/nchs\/pressroom\/nchs_press_releases\/2025\/20250514.htm. Accessed 18 Aug 2025"},{"key":"1300_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2025.104749","volume":"138","author":"A Ritter","year":"2025","unstructured":"Ritter A, Bell J, Strang J, Ezard N, Rodgers C, Belackova V, et al. Bridging the evidence and the politics: implementation trial of supervised injectable opioid treatment (SIOT) in Australia. Int J Drug Policy. 2025;138: 104749.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"1300_CR12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1192\/bjp.bp.114.149195","volume":"207","author":"J Strang","year":"2015","unstructured":"Strang J, Groshkova T, Uchtenhagen A, van den Brink W, Haasen C, Schechter MT, et al. Heroin on trial: systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addiction. Br J Psychiatry. 2015;207(1):5\u201314.","journal-title":"Br J Psychiatry"},{"key":"1300_CR13","doi-asserted-by":"crossref","unstructured":"Kilmer B, Taylor J, Caulkins J, Mueller P, Ober A, Pardo B, et al. Considering Heroin-Assisted Treatment and Supervised Drug Consumption Sites in the United States [Internet]. RAND Corporation; 2018. Available from: https:\/\/www.rand.org\/pubs\/research_reports\/RR2693.html","DOI":"10.7249\/RR2693"},{"key":"1300_CR14","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jsat.2019.03.012","volume":"101","author":"E Oviedo-Joekes","year":"2019","unstructured":"Oviedo-Joekes E, Palis H, Guh D, Marchand K, Brissette S, Harrison S, et al. Treatment with injectable hydromorphone: comparing retention in double blind and open label treatment periods. J Subst Abuse Treat. 2019;101:50\u20134.","journal-title":"J Subst Abuse Treat"},{"issue":"5","key":"1300_CR15","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1001\/jamapsychiatry.2016.0109","volume":"73","author":"E Oviedo-Joekes","year":"2016","unstructured":"Oviedo-Joekes E, Guh D, Brissette S, Marchand K, MacDonald S, Lock K, et al. Hydromorphone compared with diacetylmorphine for long-term opioid dependence. JAMA Psychiatr. 2016;73(5):447.","journal-title":"JAMA Psychiatr"},{"key":"1300_CR16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.drugalcdep.2017.02.021","volume":"176","author":"E Oviedo-Joekes","year":"2017","unstructured":"Oviedo-Joekes E, Brissette S, MacDonald S, Guh D, Marchand K, Jutha S, et al. Safety profile of injectable hydromorphone and diacetylmorphine for long-term severe opioid use disorder. Drug Alcohol Depend. 2017;176:55\u201362.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"1300_CR17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1177\/29767342231210552","volume":"45","author":"AD Fox","year":"2024","unstructured":"Fox AD, Riback L, Perez-Correa A, Ohlendorf E, Ghiroli M, Behrends CN, L\u00f3pez-Castro T. High interest in injectable opioid agonist treatment with hydromorphone among urban syringe service program participants. Subst Use Addict J. 2024;45(1):44\u201353.","journal-title":"Subst Use Addict J"},{"issue":"3","key":"1300_CR18","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.1097\/ADM.0000000000001093","volume":"17","author":"E Ohlendorf","year":"2023","unstructured":"Ohlendorf E, Perez-Correa A, Riback L, Ghiroli M, Lopez-Castro T, Fox AD. Treatment history and interest in injectable opioid agonist treatment with hydromorphone among people who inject drugs. J Addict Med. 2023;17(3):e148-55.","journal-title":"J Addict Med"},{"issue":"6","key":"1300_CR19","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1111\/add.15297","volume":"116","author":"S Nielsen","year":"2021","unstructured":"Nielsen S, Sanfilippo P, Belackova V, Day C, Silins E, Lintzeris N, et al. Perceptions of injectable opioid agonist treatment (iOAT) among people who regularly use opioids in Australia: findings from a cross-sectional study in three Australian cities. Addiction. 2021;116(6):1482\u201394.","journal-title":"Addiction"},{"key":"1300_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108459","volume":"219","author":"T Santo","year":"2021","unstructured":"Santo T, Campbell G, Gisev N, Tran LT, Colledge S, Di Tanna GL, et al. Prevalence of childhood maltreatment among people with opioid use disorder: a systematic review and meta-analysis. Drug Alcohol Depend. 2021;219: 108459.","journal-title":"Drug Alcohol Depend"},{"key":"1300_CR21","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.cpr.2017.10.012","volume":"66","author":"RK McHugh","year":"2018","unstructured":"McHugh RK, Votaw VR, Sugarman DE, Greenfield SF. Sex and gender differences in substance use disorders. Clin Psychol Rev. 2018;66:12\u201323.","journal-title":"Clin Psychol Rev"},{"issue":"1","key":"1300_CR22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13011-024-00608-8","volume":"19","author":"MN Rodr\u00edguez","year":"2024","unstructured":"Rodr\u00edguez MN, Colgan DD, Leyde S, Pike K, Merrill JO, Price CJ. Trauma exposure across the lifespan among individuals engaged in treatment with medication for opioid use disorder: differences by gender, PTSD status, and chronic pain. Subst Abuse Treat Prev Policy. 2024;19(1):25.","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"4","key":"1300_CR23","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/ajad.12921","volume":"28","author":"AS Huhn","year":"2019","unstructured":"Huhn AS, Berry MS, Dunn KE. Sex-based differences in treatment outcomes for persons with opioid use disorder. Am J Addict. 2019;28(4):246\u201361.","journal-title":"Am J Addict"},{"issue":"6\u20137","key":"1300_CR24","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.addbeh.2009.01.002","volume":"34","author":"CE Grella","year":"2009","unstructured":"Grella CE, Karno MP, Warda US, Niv N, Moore AA. Gender and comorbidity among individuals with opioid use disorders in the NESARC study. Addict Behav. 2009;34(6\u20137):498\u2013504.","journal-title":"Addict Behav"},{"issue":"2","key":"1300_CR25","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.1526-4637.2008.00558.x","volume":"10","author":"CJ Paller","year":"2009","unstructured":"Paller CJ, Campbell CM, Edwards RR, Dobs AS. Sex-based differences in pain perception and treatment. Pain Med. 2009;10(2):289\u201399.","journal-title":"Pain Med"},{"issue":"5","key":"1300_CR26","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1111\/adb.12383","volume":"21","author":"JB Becker","year":"2016","unstructured":"Becker JB, McClellan M, Reed BG. Sociocultural context for sex differences in addiction. Addict Biol. 2016;21(5):1052\u20139.","journal-title":"Addict Biol"},{"issue":"1","key":"1300_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2006.05.012","volume":"86","author":"SF Greenfield","year":"2007","unstructured":"Greenfield SF, Brooks AJ, Gordon SM, Green CA, Kropp F, McHugh RK, et al. Substance abuse treatment entry, retention, and outcome in women: a review of the literature. Drug Alcohol Depend. 2007;86(1):1\u201321.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"1300_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/0192513X15581659","volume":"39","author":"KL Stringer","year":"2018","unstructured":"Stringer KL, Baker EH. Stigma as a barrier to substance abuse treatment among those with unmet need: an analysis of parenthood and marital status. J Fam Issues. 2018;39(1):3\u201327.","journal-title":"J Fam Issues"},{"key":"1300_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109551","volume":"238","author":"T Santo","year":"2022","unstructured":"Santo T, Campbell G, Gisev N, Martino-Burke D, Wilson J, Colledge-Frisby S, et al. Prevalence of mental disorders among people with opioid use disorder: a systematic review and meta-analysis. Drug Alcohol Depend. 2022;238: 109551.","journal-title":"Drug Alcohol Depend"},{"key":"1300_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104054","volume":"117","author":"S Mayer","year":"2023","unstructured":"Mayer S, Boyd J, Fairbairn N, Chapman J, Brohman I, Jenkins E, McNeil R. Women\u2019s experiences in injectable opioid agonist treatment programs in Vancouver, Canada. Int J Drug Policy. 2023;117: 104054.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"1300_CR31","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1940-0640-9-21","volume":"9","author":"E Oviedo-Joekes","year":"2014","unstructured":"Oviedo-Joekes E, Marchand K, Lock K, Chettiar J, Marsh DC, Brissette S, et al. A chance to stop and breathe: participants\u2019 experiences in the North American opiate medication initiative clinical trial. Addict Sci Clin Pract. 2014;9(1):21.","journal-title":"Addict Sci Clin Pract"},{"issue":"3","key":"1300_CR32","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0740-5472(92)90062-S","volume":"9","author":"AT McLellan","year":"1992","unstructured":"McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, et al. The fifth edition of the addiction severity index. J Subst Abuse Treat. 1992;9(3):199\u2013213.","journal-title":"J Subst Abuse Treat"},{"issue":"3","key":"1300_CR33","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.drugpo.2013.10.015","volume":"25","author":"A Siegler","year":"2014","unstructured":"Siegler A, Tuazon E, Bradley O\u2019Brien D, Paone D. Unintentional opioid overdose deaths in New York city, 2005\u20132010: a place-based approach to reduce risk. Int J Drug Policy. 2014;25(3):569\u201374.","journal-title":"Int J Drug Policy"},{"key":"1300_CR34","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2023.2196435","author":"ST Allen","year":"2023","unstructured":"Allen ST, Schneider KE, Rouhani S, White RH, Morris M, Owczarzak J, et al. Interest in treatment with injectable diacetylmorphine among people who use opioids in Baltimore city, Maryland (USA). Ann Med. 2023. https:\/\/doi.org\/10.1080\/07853890.2023.2196435.","journal-title":"Ann Med"},{"issue":"1","key":"1300_CR35","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13011-017-0110-9","volume":"12","author":"H Palis","year":"2017","unstructured":"Palis H, Marchand K, Guh D, Brissette S, Lock K, MacDonald S, et al. Men\u2019s and women\u2019s response to treatment and perceptions of outcomes in a randomized controlled trial of injectable opioid assisted treatment for severe opioid use disorder. Subst Abuse Treat Prev Policy. 2017;12(1):25.","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"1\u20132","key":"1300_CR36","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.drugalcdep.2010.03.016","volume":"111","author":"E Oviedo-Joekes","year":"2010","unstructured":"Oviedo-Joekes E, Guh D, Brissette S, Marchand K, Marsh D, Chettiar J, et al. Effectiveness of diacetylmorphine versus methadone for the treatment of opioid dependence in women. Drug Alcohol Depend. 2010;111(1\u20132):50\u20137.","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"1300_CR37","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1080\/23744235.2020.1727002","volume":"52","author":"M K\u00e5berg","year":"2020","unstructured":"K\u00e5berg M, Karlsson N, Discacciati A, Widgren K, Weiland O, Ekstr\u00f6m AM, et al. Significant decrease in injection risk behaviours among participants in a needle exchange programme. Infect Dis. 2020;52(5):336\u201346.","journal-title":"Infect Dis"},{"key":"1300_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.103059","volume":"90","author":"N Karlsson","year":"2021","unstructured":"Karlsson N, K\u00e5berg M, Berglund T, Hammarberg A, Widman L, Ekstr\u00f6m AM. A prospective cohort study of risk behaviours, retention and loss to follow-up over 5 years among women and men in a needle exchange program in Stockholm, Sweden. Int J Drug Policy. 2021;90: 103059.","journal-title":"Int J Drug Policy"},{"issue":"5","key":"1300_CR39","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/iwj.13572","volume":"18","author":"BA Cahn","year":"2021","unstructured":"Cahn BA, Bartholomew TS, Patel HP, Pastar I, Tookes HE, Lev-Tov H. Correlates of injection\u2010related wounds and skin infections amongst persons who inject drugs and use a syringe service programme: a single center study. Int Wound J. 2021;18(5):701\u20137.","journal-title":"Int Wound J"},{"key":"1300_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103474","volume":"99","author":"BT Hayes","year":"2022","unstructured":"Hayes BT, Favaro J, Coello D, Behrends CN, Jakubowski A, Fox AD. Participants of a mail delivery syringe services program are underserved by other safe sources for sterile injection supplies. Int J Drug Policy. 2022;99: 103474.","journal-title":"Int J Drug Policy"},{"issue":"3","key":"1300_CR41","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1081\/ADA-120006736","volume":"28","author":"SB Montgomery","year":"2002","unstructured":"Montgomery SB, Hyde J, De Rosa CJ, Rohrbach LA, Ennett S, Harvey SM, et al. Gender differences in HIV risk behaviors among young injectors and their social network members. Am J Drug Alcohol Abuse. 2002;28(3):453\u201375.","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"14","key":"1300_CR42","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1081\/JA-100108439","volume":"36","author":"SG Sherman","year":"2001","unstructured":"Sherman SG, Latkin CA, Gielen AC. Social factors related to syringe sharing among injecting partners: a focus on gender. Subst Use Misuse. 2001;36(14):2113\u201336.","journal-title":"Subst Use Misuse"},{"issue":"4","key":"1300_CR43","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1093\/aje\/kwr318","volume":"175","author":"JL Evans","year":"2012","unstructured":"Evans JL, Tsui JI, Hahn JA, Davidson PJ, Lum PJ, Page K. Mortality among young injection drug users in San francisco: a 10-year follow-up of the UFO study. Am J Epidemiol. 2012;175(4):302\u20138.","journal-title":"Am J Epidemiol"},{"issue":"1","key":"1300_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-7517-4-1","volume":"4","author":"CL Miller","year":"2007","unstructured":"Miller CL, Kerr T, Strathdee SA, Li K, Wood E. Factors associated with premature mortality among young injection drug users in Vancouver. Harm Reduct J. 2007;4(1):1.","journal-title":"Harm Reduct J"},{"key":"1300_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2019.105779","volume":"126","author":"KA Brookmeyer","year":"2019","unstructured":"Brookmeyer KA, Haderxhanaj LT, Hogben M, Leichliter J. Sexual risk behaviors and STDs among persons who inject drugs: a national study. Prev Med Baltim. 2019;126: 105779.","journal-title":"Prev Med Baltim"},{"key":"1300_CR46","unstructured":"Roberts A, Mathers B, Degenhardt L. Women Who Inject Drugs: A Review of Their Risks, Experiences and Needs [Internet]. 2010 [cited 2024 Mar 14]. Available from: https:\/\/www.unodc.org\/documents\/hiv-aids\/Women_who_inject_drugs.pdf"},{"key":"1300_CR47","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202002125R","author":"TG Goetz","year":"2021","unstructured":"Goetz TG, Becker JB, Mazure CM. Women, opioid use and addiction. FASEB J. 2021. https:\/\/doi.org\/10.1096\/fj.202002125R.","journal-title":"FASEB J"},{"issue":"12","key":"1300_CR48","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1111\/add.14417","volume":"113","author":"J Boyd","year":"2018","unstructured":"Boyd J, Collins AB, Mayer S, Maher L, Kerr T, McNeil R. Gendered violence and overdose prevention sites: a rapid ethnographic study during an overdose epidemic in Vancouver, Canada. Addiction. 2018;113(12):2261\u201370.","journal-title":"Addiction"},{"issue":"10141","key":"1300_CR49","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0140-6736(18)31203-0","volume":"392","author":"CM Mazure","year":"2018","unstructured":"Mazure CM, Fiellin DA. Women and opioids: something different is happening here. Lancet. 2018;392(10141):9\u201311.","journal-title":"Lancet"},{"issue":"5","key":"1300_CR50","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3109\/00952990.2011.596982","volume":"37","author":"SE Back","year":"2011","unstructured":"Back SE, Payne RL, Wahlquist AH, Carter RE, Stroud Z, Haynes L, et al. Comparative profiles of men and women with opioid dependence: results from a national multisite effectiveness trial. Am J Drug Alcohol Abuse. 2011;37(5):313\u201323.","journal-title":"Am J Drug Alcohol Abuse"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01300-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-025-01300-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01300-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T21:48:26Z","timestamp":1757454506000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-025-01300-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1300"],"URL":"https:\/\/doi.org\/10.1186\/s12954-025-01300-1","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"assertion":[{"value":"29 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. The Institutional Review Board (IRB) at the Albert Einstein College of Medicine reviewed the study protocol (2020-12002) and determined this to be exempt research, meaning written informed consent was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"147"}}